Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R01 NS088533, R01 NS112203)
National Institutes of Health (P50 NS108675, F31 NS106733)
American Parkinson Disease Association
Parkinson Association of Alabama
Received: 25 August 2020
Accepted: 19 December 2020
First Online: 7 January 2021
Ethics approval and consent to participate
: Mice were used in accordance with the guidelines of the National Institute of Health (NIH) and University of Alabama at Birmingham (UAB) Institutional Animal Care and Use Committee (IACUC) and all experiments abided by the principles outlined in the Basel Declaration.
: Not applicable.
: Dr. Yacoubian has a U.S. Patent No. 7,919,262 on the use of 14-3-3s in neurodegeneration. The remaining authors have no competing interests to declare.